Bell Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Bell Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12	Closed	-$310	–	1913
2025 Q3	$310	Hold	12	–	–	﹤0.01%	1829
2025 Q2	$287	Hold	12	–	–	﹤0.01%	1836
2025 Q1	$299	Hold	12	–	–	﹤0.01%	1850
2024 Q4	$227	Hold	12	–	–	﹤0.01%	1865
2024 Q3	$181	Hold	12	–	–	﹤0.01%	1861
2024 Q2	$344	Hold	12	–	–	﹤0.01%	1892
2024 Q1	$351	Hold	12	–	–	﹤0.01%	1878
2023 Q4	$405	Hold	12	–	–	﹤0.01%	1867
2023 Q3	$369	Sell	12 -13	-52%	-$469	﹤0.01%	1875
2023 Q2	$1K	Sell	25 -12	-32%	-$496	﹤0.01%	1604
2023 Q1	$1.51K	Buy	37 +24	+185%	+$955	﹤0.01%	1397
2022 Q4	$502	Buy	+13	New	+$632	﹤0.01%	1836

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bell Investment Advisors's PCRX Position: Q4 2025 in Review

Bell Investment Advisors sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 12 shares — an estimated $310 sold.

Bell Investment Advisors first reported a position in PCRX in Q4 2022 and held it in 12 quarters. The position peaked at $1.51K in Q1 2023. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Bell Investment Advisors reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Bell Investment Advisors sold 12 Pacira BioSciences shares in Q4 2025, an estimated $310.
Bell Investment Advisors first reported a position in Pacira BioSciences in Q4 2022 and held it in 12 quarters.
Bell Investment Advisors's Pacira BioSciences position peaked at $1.51K in Q1 2023.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.